Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn:
“One of the most impressive roundtables I’ve ever had the pleasure of joining!
The goal: Navigating the brave new world of HER2-positive breast cancer following the practice-changing results of DESTINY-Breast09, 05, and 11.
A fascinating discussion at ESMO26 Madrid, featuring Sara Hurvitz, Neil Iyengar, Heather McArthur, Erika Hamilton, Tiffany Traina, Jason Mouabbi, and myself.
Watch the full discussion here.”
You can also read: DESTINY-Breast09 Redefines First-Line HER2-Positive Breast Cancer: Balancing Efficacy, Safety, and Treatment Selection
